Chemours (NYSE: CC) reported Q1 EPS of $0.13, $0.10 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.36 billion.

Full Year 2025 Outlook

The Company expects to deliver Adjusted EBITDA of $825 million to $950 million in 2025. Anticipated capital expenditures are expected to range between $225 million to $275 million, and while anticipating free cash flow to be slightly positive in the second quarter, the Company projects free cash flows conversion to be in the range of 60-80% in the second half. This outlook assumes the existing tariff environment and known direct impacts to the business and no larger indirect impacts from tariffs on the macroeconomic environment or recessionary impacts.

For earnings history and earnings-related data on Chemours (CC) click here.